CN1894210A - 脯氨酸基芳基乙酰胺 - Google Patents

脯氨酸基芳基乙酰胺 Download PDF

Info

Publication number
CN1894210A
CN1894210A CNA2004800376989A CN200480037698A CN1894210A CN 1894210 A CN1894210 A CN 1894210A CN A2004800376989 A CNA2004800376989 A CN A2004800376989A CN 200480037698 A CN200480037698 A CN 200480037698A CN 1894210 A CN1894210 A CN 1894210A
Authority
CN
China
Prior art keywords
phenyl
methylamino
dicarboxamide
compound
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800376989A
Other languages
English (en)
Chinese (zh)
Inventor
W·梅德尔斯基
C·察克拉基迪斯
D·多尔施
B·切赞内
J·格莱茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN1894210A publication Critical patent/CN1894210A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CNA2004800376989A 2003-12-16 2004-11-26 脯氨酸基芳基乙酰胺 Pending CN1894210A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10358814.0 2003-12-16
DE10358814A DE10358814A1 (de) 2003-12-16 2003-12-16 Prolinylarylacetamide

Publications (1)

Publication Number Publication Date
CN1894210A true CN1894210A (zh) 2007-01-10

Family

ID=34683363

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800376989A Pending CN1894210A (zh) 2003-12-16 2004-11-26 脯氨酸基芳基乙酰胺

Country Status (16)

Country Link
US (1) US7732481B2 (https=)
EP (1) EP1697318B1 (https=)
JP (1) JP4800969B2 (https=)
KR (1) KR20060113729A (https=)
CN (1) CN1894210A (https=)
AR (1) AR046765A1 (https=)
AT (1) ATE406350T1 (https=)
AU (1) AU2004299197B2 (https=)
BR (1) BRPI0417630A (https=)
CA (1) CA2549589A1 (https=)
DE (2) DE10358814A1 (https=)
ES (1) ES2310772T3 (https=)
MX (1) MXPA06006740A (https=)
RU (1) RU2006125509A (https=)
WO (1) WO2005058817A1 (https=)
ZA (1) ZA200605841B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109761957A (zh) * 2019-01-18 2019-05-17 西安交通大学 一种含有羟脯氨酸的化合物及其制备方法和应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1818330A1 (de) 2006-02-14 2007-08-15 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Prolinamide, deren Herstellung und deren Verwendung als Arzneimittel
MY146623A (en) 2006-05-16 2012-09-14 Boehringer Ingelheim Int Substituted prolinamides, manufacturing, and the use thereof as medicaments
WO2009000878A1 (en) * 2007-06-28 2008-12-31 Novartis Ag Kallikrein 7 modulators
WO2011027888A1 (ja) * 2009-09-07 2011-03-10 大日本住友製薬株式会社 ジアミド－フェニル誘導体、またはその薬学的に許容される塩

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
BRPI0408444A (pt) * 2003-04-03 2006-04-04 Merck Patent Gmbh derivados de 1-n-(fenil)-2-n-(fenil) pirazolidina-1,2-dicarboxamida como inibidores de fator xa de coagulação para o tratamento de trombose
PL377633A1 (pl) * 2003-04-03 2006-02-06 Merck Patent Gmbh Związki karbonylowe
DE102004014945A1 (de) * 2004-03-26 2005-10-13 Merck Patent Gmbh Prolinylderivate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109761957A (zh) * 2019-01-18 2019-05-17 西安交通大学 一种含有羟脯氨酸的化合物及其制备方法和应用

Also Published As

Publication number Publication date
KR20060113729A (ko) 2006-11-02
DE502004007959D1 (de) 2008-10-09
ZA200605841B (en) 2007-10-31
US7732481B2 (en) 2010-06-08
DE10358814A1 (de) 2005-07-21
JP4800969B2 (ja) 2011-10-26
AU2004299197B2 (en) 2010-08-05
EP1697318B1 (de) 2008-08-27
MXPA06006740A (es) 2006-08-18
US20070185189A1 (en) 2007-08-09
WO2005058817A1 (de) 2005-06-30
ATE406350T1 (de) 2008-09-15
JP2007513988A (ja) 2007-05-31
EP1697318A1 (de) 2006-09-06
AR046765A1 (es) 2005-12-21
RU2006125509A (ru) 2008-01-27
CA2549589A1 (en) 2005-06-30
ES2310772T3 (es) 2009-01-16
BRPI0417630A (pt) 2007-03-27
AU2004299197A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
CN101031561A (zh) 可以用作凝血因子xa抑制剂的羰基化合物
CN1273128C (zh) 取代的n－[(氨基亚氨基甲基或氨基甲基)苯基]丙基酰胺
CN1481358A (zh) 酰胺衍生物和它们在治疗血栓栓塞性疾病和肿瘤中的用途
CN1845921A (zh) 金刚烷和氮杂双环－辛烷及壬烷衍生物、其制备方法及其作为dpp－iv抑制剂的用途
CN1809346A (zh) 作为凝血因子xa和viia的抑制剂用于治疗形成血栓的1－[(4－乙炔基苯基) ]－2－[(苯基)]－吡咯烷－1,2－二酰胺衍生物
CN1678317A (zh) 用作治疗呕吐、抑郁症、焦虑症和咳嗽的神经激肽－1(nk－1)拮抗剂的1－酰氨基－4－苯基－4－苄氧基甲基－哌啶衍生物和相关化合物
CN1454211A (zh) 作为Xa因子抑制剂的含氮杂双环化合物
CN1518541A (zh) 苯基衍生物
CN1639119A (zh) 取代的2－氨基－环烷烃甲酰胺和它们作为半胱氨酸蛋白酶抑制剂的用途
KR20100066580A (ko) 글루코키나아제 활성인자로서의 ｎ-(피라졸-3-일)-벤즈아미드 유도체
CN1681789A (zh) 1－吡啶－4－基－脲衍生物
CN1496361A (zh) 苯基衍生物3
CN1771237A (zh) 在治疗血栓栓塞性疾病中用作凝血因子 x a抑制剂的 1 － (苯基氨基甲酰基 ) － 2 － ( 4 － ( 3 －氧代－吗啉 － 4－基 ) －苯基氨基甲酰基)吡咯烷衍生物及相关化合物
CN1890216A (zh) 羧酸胺衍生物
CN1342148A (zh) 用作因子Xa抑制剂的吡唑－3－酮衍生物
CN1894210A (zh) 脯氨酸基芳基乙酰胺
CN1741996A (zh) 酰胺衍生物及其作为因子xa抑制剂的用途
CN1582148A (zh) 作为凝血因子Xa抑制剂用于治疗血栓栓塞性疾病和肿瘤的苯氧基－N－′4－(1,1－二氧代异噻唑烷－2－基)苯基!－戊酰胺衍生物及其它化合物
CN1538845A (zh) 作为Xa因子抑制剂的苯基衍生物
CN1665506A (zh) 作为ccr－3受体拮抗剂ⅸ的2,5－取代的嘧啶衍生物
CN1119344C (zh) 杂环取代的新型吡咯烷酰胺衍生物
CN1914184A (zh) 脲衍生物
CN1443160A (zh) N－取代的1－氨基－1,1－二烷基羧酸衍生物
CN101031566A (zh) 脯氨酸衍生物
HK1063779A (en) Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication